全文获取类型
收费全文 | 36594篇 |
免费 | 2248篇 |
国内免费 | 52篇 |
专业分类
耳鼻咽喉 | 476篇 |
儿科学 | 1030篇 |
妇产科学 | 781篇 |
基础医学 | 6325篇 |
口腔科学 | 572篇 |
临床医学 | 2895篇 |
内科学 | 6818篇 |
皮肤病学 | 683篇 |
神经病学 | 3365篇 |
特种医学 | 1366篇 |
外国民族医学 | 8篇 |
外科学 | 4761篇 |
综合类 | 125篇 |
一般理论 | 19篇 |
预防医学 | 3507篇 |
眼科学 | 640篇 |
药学 | 2766篇 |
中国医学 | 38篇 |
肿瘤学 | 2719篇 |
出版年
2023年 | 166篇 |
2022年 | 228篇 |
2021年 | 514篇 |
2020年 | 368篇 |
2019年 | 484篇 |
2018年 | 688篇 |
2017年 | 570篇 |
2016年 | 621篇 |
2015年 | 710篇 |
2014年 | 914篇 |
2013年 | 1314篇 |
2012年 | 1961篇 |
2011年 | 1976篇 |
2010年 | 1029篇 |
2009年 | 1048篇 |
2008年 | 1724篇 |
2007年 | 1813篇 |
2006年 | 1797篇 |
2005年 | 1771篇 |
2004年 | 1617篇 |
2003年 | 1566篇 |
2002年 | 1473篇 |
2001年 | 1062篇 |
2000年 | 1104篇 |
1999年 | 1012篇 |
1998年 | 444篇 |
1997年 | 421篇 |
1996年 | 429篇 |
1995年 | 386篇 |
1994年 | 351篇 |
1993年 | 342篇 |
1992年 | 679篇 |
1991年 | 581篇 |
1990年 | 617篇 |
1989年 | 655篇 |
1988年 | 535篇 |
1987年 | 499篇 |
1986年 | 428篇 |
1985年 | 458篇 |
1984年 | 339篇 |
1983年 | 289篇 |
1982年 | 189篇 |
1981年 | 241篇 |
1980年 | 202篇 |
1979年 | 243篇 |
1978年 | 161篇 |
1977年 | 173篇 |
1976年 | 137篇 |
1975年 | 144篇 |
1974年 | 136篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
981.
982.
983.
Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease 总被引:7,自引:0,他引:7 下载免费PDF全文
Binks M Passweg JR Furst D McSweeney P Sullivan K Besenthal C Finke J Peter HH van Laar J Breedveld FC Fibbe WE Farge D Gluckman E Locatelli F Martini A van den Hoogen F van de Putte L Schattenberg AV Arnold R Bacon PA Emery P Espigado I Hertenstein B Hiepe F Kashyap A Kötter I Marmont A Martinez A Pascual MJ Gratwohl A Prentice HG Black C Tyndall A 《Annals of the rheumatic diseases》2001,60(6):577-584
BACKGROUND: Systemic sclerosis (SSc, scleroderma) in either its diffuse or limited skin forms has a high mortality when vital organs are affected. No treatment has been shown to influence the outcome or significantly affect the skin score, though many forms of immunosuppression have been tried. Recent developments in haemopoietic stem cell transplantation (HSCT) have allowed the application of profound immunosuppression followed by HSCT, or rescue, to autoimmune diseases such as SSc. METHODS: Results for 41 patients included in continuing multicentre open phase I/II studies using HSCT in the treatment of poor prognosis SSc are reported. Thirty seven patients had a predominantly diffuse skin form of the disease and four the limited form, with some clinical overlap. Median age was 41 years with a 5:1 female to male ratio. The skin score was >50% of maximum in 20/33 (61%) patients, with some lung disease attributable to SSc in 28/37 (76%), the forced vital capacity being <70% of the predicted value in 18/36 (50%). Pulmonary hypertension was described in 7/37 (19%) patients and renal disease in 5/37 (14%). The Scl-70 antibody was positive in 18/32 (56%) and the anticentromere antibody in 10% of evaluable patients. Peripheral blood stem cell mobilisation was performed with cyclophosphamide or granulocyte colony stimulating factor, alone or in combination. Thirty eight patients had ex vivo CD34 stem cell selection, with additional T cell depletion in seven. Seven conditioning regimens were used, but six of these used haemoimmunoablative doses of cyclophosphamide +/- anti-thymocyte globulin +/- total body irradiation. The median duration of follow up was 12 months (3-55). RESULTS: An improvement in skin score of >25% after transplantation occurred in 20/29 (69%) evaluable patients, and deterioration in 2/29 (7%). Lung function did not change significantly after transplantation. One of five renal cases deteriorated but with no new occurrences of renal disease after HSCT, and the pulmonary hypertension did not progress in the evaluable cases. Disease progression was seen in 7/37 (19%) patients after HSCT with a median period of 67 (range 49-255) days. Eleven (27%) patients had died at census and seven (17%) deaths were considered to be related to the procedure (direct organ toxicity in four, haemorrhage in two, and infection/neutropenic fever in one). The cumulative probability of survival at one year was 73% (95% CI 58 to 88) by Kaplan-Meier analysis. CONCLUSION: Despite a higher procedure related mortality rate from HSCT in SSc compared with patients with breast cancer and non-Hodgkin's lymphoma, the marked impact on skin score, a surrogate marker of mortality, the trend towards stabilisation of lung involvement, and lack of other treatment alternatives justify further carefully designed studies. If future trials incorporate inclusion and exclusion criteria based on this preliminary experience, the predicted procedure related mortality should be around 10%. 相似文献
984.
985.
Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAX‐AHF‐2 study 下载免费PDF全文
John R. Teerlink Adriaan A. Voors Piotr Ponikowski Peter S. Pang Barry H. Greenberg Gerasimos Filippatos G. Michael Felker Beth A. Davison Gad Cotter Claudio Gimpelewicz Leandro Boer‐Martins Margaret Wernsing Tsushung A. Hua Thomas Severin Marco Metra 《European journal of heart failure》2017,19(6):800-809
Patients admitted for acute heart failure (AHF) experience high rates of in‐hospital and post‐discharge morbidity and mortality despite current therapies. Serelaxin is recombinant human relaxin‐2, a hormone with vasodilatory and end‐organ protective effects believed to play a central role in the cardiovascular and renal adaptations of human pregnancy. In the phase 3 RELAX‐AHF trial, serelaxin met its primary endpoint of improving dyspnoea through day 5 in patients admitted for AHF. Compared to placebo, serelaxin also reduced worsening heart failure (WHF) by 47% through day 5 and both all‐cause and cardiovascular mortality by 37% through day 180. RELAX‐AHF‐2 ( ClinicalTrials.gov NCT01870778) is designed to confirm serelaxin's effect on these clinical outcomes. RELAX‐AHF‐2 is a multicentre, randomized, double‐blind, placebo‐controlled, event‐driven, phase 3 trial enrolling ~6800 patients hospitalized for AHF with dyspnoea, congestion on chest radiograph, increased natriuretic peptide levels, mild‐to‐moderate renal insufficiency, and systolic blood pressure ≥125 mmHg. Patients are randomized within 16 h of presentation to 48 h intravenous infusions of serelaxin (30 µg/kg/day) or placebo, both in addition to standard of care treatments. The primary objectives are to demonstrate that serelaxin is superior to placebo in reducing: (i) 180 day cardiovascular death, and (ii) occurrence of WHF through day 5. Key secondary endpoints include 180 day all‐cause mortality, composite of 180 day combined cardiovascular mortality or heart failure/renal failure rehospitalization, and in‐hospital length of stay during index AHF. The results from RELAX‐AHF‐2 will provide data on the potential beneficial effect of serelaxin on cardiovascular mortality and WHF in selected patients with AHF. 相似文献
986.
Ingrid A.W. van Rijsingen Eloisa Arbustini Perry M. Elliott Jens Mogensen Johanna F. Hermans-van Ast Anneke J. van der Kooi J. Peter van Tintelen Maarten P. van den Berg Andrea Pilotto Michele Pasotti Sharon Jenkins Camilla Rowland Uzma Aslam Arthur A.M. Wilde Andreas Perrot Sabine Pankuweit Aeilko H. Zwinderman Philippe Charron Yigal M. Pinto 《Journal of the American College of Cardiology》2012
987.
988.
Marka van Blitterswijk Michael A. van Es Max Koppers Wouter van Rheenen Jelena Medic Helenius J. Schelhaas Anneke J. van der Kooi Marianne de Visser Jan H. Veldink Leonard H. van den Berg 《Neurobiology of aging》2012
Previously, we have reported amyotrophic lateral sclerosis (ALS) families with multiple mutations in major ALS-associated genes. These findings provided evidence for an oligogenic basis of ALS. In our present study, we screened a cohort of 755 sporadic ALS patients, 111 familial ALS patients (97 families), and 765 control subjects of Dutch descent for mutations in vesicle-associated membrane protein B (VAPB). We have identified 1 novel VAPB mutation (p.V234I) in a familial ALS patient known to have a chromosome 9 open reading frame 72 (C9orf72) repeat expansion. This p.V234I mutation was absent in control subjects, located in a region with high evolutionary conservation, and predicted to have damaging effects. Taken together, these findings provide additional evidence for an oligogenic basis of ALS. 相似文献
989.
W W Layne A I Kassis A Van den Abbeele B M Kinsey S J Adelstein 《Journal of immunological methods》1987,96(2):195-199
Rabbit immunoglobulin G (RIgG) was reduced with dithioerythritol and analyzed by high performance liquid chromatography. A quantitative method for determining the percentage of reduced half-molecules in the mixture was developed. An acetic acid concentration-dependent rate of dissociation of reduced half-molecules was observed. The specific optical absorptivity was determined for whole molecules and half-molecules and found to be significantly greater for the half-molecules. Purified half-molecules were reconstituted into RIgG with a yield greater than 90% following a 16 h incubation at pH 8.0 and room temperature. 相似文献
990.
El-Sheikh AA van den Heuvel JJ Koenderink JB Russel FG 《The Journal of pharmacology and experimental therapeutics》2007,320(1):229-235
Methotrexate (MTX) has been used in combination with nonsteroidal anti-inflammatory drugs (NSAIDs) in the treatment of inflammatory diseases as well as malignancies. Especially at high MTX dosages, severe adverse effects with this combination may occur, usually resulting from an impaired renal elimination. It has been shown that the mechanism of this interaction cannot be fully attributed to inhibition of basolateral MTX uptake in renal proximal tubules. Here, we studied the effect of various NSAIDs on MTX transport in membrane vesicles isolated from cells overexpressing the proximal tubular apical efflux transporters human multidrug resistance protein (MRP) 2/ABCC2 and MRP4/ABCC4. MTX was transported by MRP2 and MRP4 with Km values of 480 +/- 90 and 220 +/- 70 microM, respectively. The inhibitory potency of the NSAIDs was generally higher against MRP4- than MRP2-mediated MTX transport, with therapeutically relevant IC50 values, ranging from approximately 2 microM to 1.8 mM. Salicylate, piroxicam, ibuprofen, naproxen, sulindac, tolmetin, and etodolac inhibited MRP2- and MRP4-mediated MTX transport according to a one-site competition model. In some cases, more complex interaction patterns were observed. Inhibition of MRP4 by diclofenac and MRP2 by indomethacin and ketoprofen followed a two-site competition model. Phenylbutazone stimulated MRP2 and celecoxib MRP4 transport at low concentrations and inhibited both transporters at high concentration. Our data suggest that the inhibition by NSAIDs of renal MTX efflux via MRP2 and MRP4 is a potential new site and mechanism contributing to the overall interaction between these drugs. 相似文献